Related references
Note: Only part of the references are listed.The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies
Anke Van der Perren et al.
ACTA NEUROPATHOLOGICA (2020)
New insights on the structure of alpha-synuclein fibrils using cryo-electron microscopy
Ricardo Guerrero-Ferreira et al.
CURRENT OPINION IN NEUROBIOLOGY (2020)
LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Changyoun Kim et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders
Sireesha Manne et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2019)
Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
Keita Kakuda et al.
SCIENTIFIC REPORTS (2019)
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease
Qian-hang Shao et al.
ACTA PHARMACOLOGICA SINICA (2019)
Neuroinflammation as a Common Feature of Neurodegenerative Disorders
Leonardo Guzman-Martinez et al.
FRONTIERS IN PHARMACOLOGY (2019)
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
Somin Kwon et al.
EXPERIMENTAL NEUROBIOLOGY (2019)
TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model
Michela Campolo et al.
BRAIN BEHAVIOR AND IMMUNITY (2019)
Cell Responses to Extracellular α-Synuclein
Alexei A. Surguchev et al.
MOLECULES (2019)
Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2
Pietro La Vitola et al.
BRAIN BEHAVIOR AND IMMUNITY (2018)
Non-cell-autonomous actions of alpha-synuclein: Implications in glial synucleinopathies
Somin Lim et al.
PROGRESS IN NEUROBIOLOGY (2018)
Cryo-EM structure of alpha-synuclein fibrils
Ricardo Guerrero-Ferreira et al.
ELIFE (2018)
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Changyoun Kim et al.
MOLECULAR NEURODEGENERATION (2018)
Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology
Nicolas Dzamko et al.
ACTA NEUROPATHOLOGICA (2017)
Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type
Elisabet Ihse et al.
SCIENTIFIC REPORTS (2017)
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Xiaobo Mao et al.
SCIENCE (2016)
Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Changyoun Kim et al.
SCIENTIFIC REPORTS (2016)
Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease
Changyoun Kim et al.
JOURNAL OF NEUROINFLAMMATION (2015)
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy
Changyoun Kim et al.
CELL REPORTS (2015)
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
Brian Spencer et al.
MOLECULAR THERAPY (2014)
Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases
He-Jin Lee et al.
NATURE REVIEWS NEUROLOGY (2014)
β1-integrin-dependent migration of microglia in response to neuron-released α-synuclein
Changyoun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2014)
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia
Lisa Fellner et al.
GLIA (2013)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
α-Synucleinopathy phenotypes
Heather McCann et al.
PARKINSONISM & RELATED DISORDERS (2013)
Extracellular Regulated Kinase 1/2 Signaling Is a Critical Regulator of Interleukin-1β-Mediated Astrocyte Tissue Inhibitor of Metalloproteinase-1 Expression
Jerel Fields et al.
PLOS ONE (2013)
Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia
Changyoun Kim et al.
NATURE COMMUNICATIONS (2013)
Exosomal cell-to-cell transmission of alpha synuclein oligomers
Karin M. Danzer et al.
MOLECULAR NEURODEGENERATION (2012)
Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons
Nadia Stefanova et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
Christian Hansen et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Paula Desplats et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clearance and deposition of extracellular α-synuclein aggregates in microglia
He-Jin Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Controlling the mass action of alpha-synuclein in Parkinson's disease
Changyoun Kim et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Invited Article: Nervous system pathology in sporadic Parkinson disease
Heiko Braak et al.
NEUROLOGY (2008)
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein
Wei Zhang et al.
GLIA (2007)
Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway
HJ Lee et al.
JOURNAL OF NEUROSCIENCE (2004)
Dopaminergic loss and inclusion body formation in α-synuclein mice:: Implications for neurodegenerative disorders
E Masliah et al.
SCIENCE (2000)
Share Paper
